Furui Co.,Ltd(SZ:300049) Xin Lang Cai Jing·2025-10-31 02:08Core Viewpoint - Furuya Co., Ltd. has shown significant stock performance with a year-to-date increase of 127.20%, despite recent fluctuations in trading volume and net capital outflow [1][2]. Company Overview - Furuya Co., Ltd. is located in Chaoyang District, Beijing, and was established on December 26, 2001, with its listing date on January 20, 2010. The company specializes in the production and sales of pharmaceuticals, instrument research and development, and medical services, particularly in the field of liver disease [1]. - The revenue composition of Furuya Co., Ltd. is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1]. Financial Performance - For the period from January to September 2025, Furuya Co., Ltd. achieved a revenue of 1.101 billion yuan, representing a year-on-year growth of 12.37%. The net profit attributable to shareholders was 112 million yuan, reflecting a growth of 9.69% [2]. - The company has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.61 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Furuya Co., Ltd. was 26,700, an increase of 3.24% from the previous period. The average number of circulating shares per person decreased by 3.09% to 8,742 shares [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with some shareholders reducing their holdings while new shareholders have entered [3].